Rapid health technology assessment of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
- VernacularTitle:SGLT-2抑制剂治疗2型糖尿病的快速卫生技术评估
- Author:
Huimin PAN
1
;
Yubo WANG
1
;
Huiting SHAN
1
;
Ji CHEN
1
;
Jianhua YANG
2
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830011，China;Xinjiang Key Laboratory of Clinical Drug Research，Urumqi 830011，China
2. Dept. of Pharmacy，the First Affiliated Hospital of Xinjiang Medical University，Urumqi 830011，China
- Publication Type:Journal Article
- Keywords:
SGLT-2 inhibitors;
type 2 diabetes mellitus;
rapid health technology assessment;
canagliflozin;
dapagliflozin
- From:
China Pharmacy
2025;36(23):2978-2984
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the safety， efficacy， and cost-effectiveness of sodium-glucose co-transporter 2 （SGLT-2） inhibitors for treating type 2 diabetes mellitus （T2DM）. METHODS Retrieved databases such as PubMed， Cochrane Library， Embase， CNKI， as well as relevant health technology assessment （HTA） official websites， HTA reports， systematic review/meta- analysis and pharmacoeconomic studies about SGLT-2 inhibitors （including 12 types such as canagliflozin， dapagliflozin， and empagliflozin） in the treatment of T2DM were collected from the inception to January 28， 2025. After literature screening data extraction and quality assessment， a descriptive analysis was conducted on the results of the included studies. RESULTS A total of 38 articles were included， comprising 30 systematic reviews/meta-analyses， 4 pharmacoeconomic studies， and 4 HTA reports. In terms of effectiveness， most research results showed that canagliflozin was effective in controlling blood glucose， reducing body weight， and lowering blood pressure compared to other SGLT-2 inhibitors， while empagliflozin could effectively reduce all-cause mortality. In terms of safety， compared with other SGLT-2 inhibitors， empagliflozin has a lower overall adverse event rate and cardiovascular death risk， canagliflozin presented a higher risk of hypoglycemia， and dapagliflozin had a higher risk of urinary tract infections. In terms of economics， empagliflozin possessed greater economic advantages over both dapagliflozin and canagliflozin， while canagliflozin offered more benefits than dapagliflozin. CONCLUSIONS The selection of SGLT-2 inhibitors for the treatment of T2DM should be individualized. Canagliflozin is recommended for patients with high cardiovascular risk. Empagliflozin boasts the best overall safety profile. Dapagliflozin should be used with caution in patients at high risk of urinary tract infections. Based on foreign economic evidence， empagliflozin has economic advantages. In the future， drug economic studies under the Chinese health system need to be conducted.
